Back to Search Start Over

Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.

Authors :
Lee KM
Lin CC
Servetto A
Bae J
Kandagatla V
Ye D
Kim G
Sudhan DR
Mendiratta S
González Ericsson PI
Balko JM
Lee J
Barnes S
Malladi VS
Tabrizi S
Reddy SM
Yum S
Chang CW
Hutchinson KE
Yost SE
Yuan Y
Chen ZJ
Fu YX
Hanker AB
Arteaga CL
Source :
Cancer immunology research [Cancer Immunol Res] 2022 Jul 01; Vol. 10 (7), pp. 829-843.
Publication Year :
2022

Abstract

The MYC oncogene is frequently amplified in triple-negative breast cancer (TNBC). Here, we show that MYC suppression induces immune-related hallmark gene set expression and tumor-infiltrating T cells in MYC-hyperactivated TNBCs. Mechanistically, MYC repressed stimulator of interferon genes (STING) expression via direct binding to the STING1 enhancer region, resulting in downregulation of the T-cell chemokines CCL5, CXCL10, and CXCL11. In primary and metastatic TNBC cohorts, tumors with high MYC expression or activity exhibited low STING expression. Using a CRISPR-mediated enhancer perturbation approach, we demonstrated that MYC-driven immune evasion is mediated by STING repression. STING repression induced resistance to PD-L1 blockade in mouse models of TNBC. Finally, a small-molecule inhibitor of MYC combined with PD-L1 blockade elicited a durable response in immune-cold TNBC with high MYC expression, suggesting a strategy to restore PD-L1 inhibitor sensitivity in MYC-overexpressing TNBC.<br /> (©2022 American Association for Cancer Research.)

Details

Language :
English
ISSN :
2326-6074
Volume :
10
Issue :
7
Database :
MEDLINE
Journal :
Cancer immunology research
Publication Type :
Academic Journal
Accession number :
35561311
Full Text :
https://doi.org/10.1158/2326-6066.CIR-21-0826